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Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and
Food Allergens (NDA) was asked to deliver an opinion on an application for cetylated fatty acids as a
novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF concerns primarily a mixture of
cetylated myristic acid and cetylated oleic acid synthesised from cetyl alcohol, myristic acid and oleic
acid, and to a lesser degree, other cetylated fatty acids and other compounds from olive oil. The NF is
intended for use in food supplements for the general adult population. The highest dose tested in a
subchronic toxicity study in rats, i.e. 4,500 mg/kg per day, was considered to be the no-observed-
adverse effect level. By applying the default uncertainty factor of 200 as suggested by the EFSA
Scientific Committee (2012), and considering a default body weight of 70 kg for the adult target
population, this would result in an intake of 1.6 g per day, which is lower than the maximum intake
proposed by the applicant (i.e. 2.1 g per day). The Panel concludes that the NF, cetylated fatty acids,
is safe at an intake of 1.6 g per day for the intended target population, i.e. adults.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
On 4 June 2020, the company Pharmanutra S.p.A. submitted a request to the European
Commission in accordance with Article 10 of Regulation (EU) 2015/22831 to authorise placing on the
Union market of cetylated fatty acids (CFA) as a novel food.
The application requests to authorise use of cetylated fatty acids in food supplements as defined in
Directive 2002/46/EC2, excluding food supplements for infants and young children.
The applicant has also requested data protection in accordance with Article 26 of Regulation (EU)
2015/2283.
In accordance with Article 10(3) of Regulation (EU) 2015/2283, the European Commission asks the
European Food Safety Authority to provide a scientific opinion on CFA as a novel food.
In addition, the European Food Safety Authority is requested to include in its scientific opinion a
statement as to if, and if so to what extent, the proprietary data for which the applicant is requesting
data protection was used in elaborating the opinion in line with the requirements of Article 26(2)(c) of
Regulation (EU) 2015/2283.
1.2. Additional information
In 2010, EFSA published an opinion of the NDA Panel on the safety of ‘Cetyl Myristoleate Complex
(CMC)’ (EFSA NDA Panel, 2010). Besides excipients (corn starch and silicon dioxide) that Novel Food
was composed of an oil which contained mainly cetylated fatty acids (CFAs). Cetylated fatty acids are
fatty acids esterified with the long-chain (C16) aliphatic (linear), saturated, primary alcohol cetyl
alcohol (1-hexadecanol, palmityl alcohol). The oil’s major components were the esters cetyl (=palmityl)
myristate and cetyl (palmityl) myristoleate (each about 40% of that oil). Considering the absence of
appropriate data on absorption, distribution, metabolism and excretion, particular for CFAs, which
potentially may not be hydrolysed in the human gut and be absorbed intact as an ester, and no
subchronic toxicity study reported, the Panel considered that the toxicological data provided were
insufficient. Regarding genotoxicity, the EFSA NDA Panel noted references from the literature provided
by the applicant which reported negative results for myristic acid and cetyl alcohol.
In 2013, in their response to a request from the Commission to review and update its opinion from
2010, additional references and a study report of a new subchronic 90-day oral toxicity with ‘CMC’ study
were taken into account by the EFSA NDA Panel, 2013. The no observed adverse effect levels (NOAELs) of
long-chain alcohols, including cetyl alcohol in repeated toxicity studies (OECD, 2006; Veenstra et al., 2009)
were noted to be all in a similar range, with the lowest value at 750 mg/kg body weight (bw) per day based
on cetyl alcohol. The NDA Panel noted that apart from information on the safety of the hydrolysis-derived
moieties (i.e. cetyl alcohol and the concerned fatty acids), and in the absence of sufficient data on kinetics
of hydrolysis, adequate safety information on the parent compound ‘CMC’ (i.e. CFAs) remained relevant.
The NDA Panel also noted the shortcomings of the provided subchronic toxicity study and reiterated their
conclusion from 2010 that the safety of ‘CMC’ has not been established (EFSA NDA Panel, 2013).
In 2009 and 2012, the EFSA CONTAM Panel assessed also the toxicological profile of fatty alcohols
including cetyl alcohol, and esters made of fatty acids (including myristic acid, myristoleic acid, oleic
acid and others) and fatty alcohols (including cetyl alcohol) (EFSA CONTAM Panel, 2009, 2012).
However, these assessments were conducted in another context, i.e. regarding residual substances in
previous cargoes for edible fats and oils with very low potential exposure to these substances.
2. Data and methodologies
2.1. Data
The safety assessment of this NF is based on data supplied in the application and information
submitted by the applicant following EFSA request for supplementary information.
Administrative and scientific requirements for NF applications referred to in Article 10 of Regulation
(EU) 2015/2283 are listed in the Commission Implementing Regulation (EU) 2017/24691.
A common and structured format on the presentation of NF applications is described in the EFSA
guidance on the preparation and presentation of an NF application (EFSA NDA Panel, 2016). As
1 Commission Implementing Regulation (EU) 2017/2469 of 20 December 2017 laying down administrative and scientific
requirements for applications referred to in Article 10 of Regulation (EU) 2015/2283 of the European Parliament and of the
Council on novel foods. OJ L 351, 30.12.2017, pp. 64–71.
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indicated in this guidance, it is the duty of the applicant to provide all of the available (proprietary,
confidential and published) scientific data (including both data in favour and not in favour) that are
pertinent to the safety of the NF.
This NF application includes a request for protection of proprietary data in accordance with Article 26
of Regulation (EU) 2015/2283. The data requested by the applicant to be protected comprise
unpublished study reports on: an in vitro bacterial reverse mutation assay (Thompson, 2017), an in vitro
micronucleus test (Morris, 2017), a subacute (Piras, 2019) and a subchronic toxicity study (Piras, 2020)
including a summary table of statistically significant observations in toxicity studies (Appendix B3). Data
protection was also requested for Annex III (certificates of analysis, batch testing and methods of
analysis) and annex IV (stability data).
2.2. Methodologies
The assessment follows the methodology set out in the EFSA guidance on NF applications (EFSA NDA
Panel, 2016) and the principles described in the relevant existing guidance documents from the EFSA
Scientific Committee. The legal provisions for the assessment are laid down in Article 11 of Regulation
(EU) 2015/2283 and in Article 7 of the Commission Implementing Regulation (EU) 2017/2469.
This assessment concerns only the risks that might be associated with consumption of the NF
under the proposed conditions of use, and is not an assessment of the efficacy of the NF with regard
to any claimed benefit.
3. Assessment
3.1. Introduction
In accordance to Article 3 of the Novel Food Regulation (EU) 2015/2283, the NF falls under
category (i), i.e. food with a new or intentionally modified molecular structure, where that structure
was not used as, or in, a food within the Union before 15 May 1997.
3.2. Identity of the NF
The NF is a mixture composed of cetylated fatty acids (about 83%) which are esters made from cetyl
alcohol (synonyms: 1-hexadecanol, palmityl alcohol) (CAS number: 36653-82-4) and fatty acids, primarily
myristic acid (CAS number: 544-63-8) and oleic acid (CAS number: 112-80-1). It contains also smaller
amounts of other cetylated fatty acids from esterification of other fatty acids (such as linoleic and palmitic
acid) contained in refined olive oil (CAS number: 8001-25-0) and about 17% triglycerides.
3.3. Production process
The applicant provided the certificates of analysis (CoA) of the raw materials used. According to these
files, all raw materials are food grade. The raw material ‘myristic acid’ contains 99.8% myristic acid
(≥ 99%) and maximum 1% shorter or longer FAs. ‘Oleic acid’ contains at least 78% oleic acid, maximum
13% linoleic acid (C18:2), maximum 6% palmitic acid (C16) and smaller amounts of shorter (≤ C14) or
longer (≥ C20) FAs including traces of polyunsaturated FAs (e.g. ≤ 0.5% a-linolenic acid, C18:3). The CoA
for cetyl alcohol indicated a minimum content of 98% and a maximum content of hydrocarbons of 0.5%.
According to the applicant, CFAs are manufactured in compliance with the principles of Hazard
Analysis Critical Control Points (HACCP) and Good Manufacturing Practice (GMP) and are accredited
with International Organization for Standardization (ISO) 9001:2015, 22000:2005, 14001:2015 and
18001:2007. The manufacturing process does not use any extraction solvents and includes heating
and filtration steps to remove any potential contaminants. Furthermore, all starting materials used in
the production of cetylated fatty acids are food grade.
Cetyl esters are first synthesised by reacting cetyl alcohol with myristic acid and oleic acid in the
presence of a zinc catalyst under high temperature. After cooling, the refined cetyl esters undergo
decolourisation, and are again mixed with olive oil at high temperature. Further deodorisation,
neutralisation and filtration yield the final ingredient. The NF is stored in aluminium boxes.
The Panel considers that the production process is sufficiently described.
3.4. Compositional data
Five independently produced batches show that the NF consists mainly of the cetylated fatty acids
cetyl myristate and cetyl oleate, and triglycerides (Table 1). The triglycerides and the oleic acid moiety
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of cetyl oleate originate from olive oil. CoAs are provided. The analyses of the esters and the
triglycerides were performed using gas chromatography with flame ionisation detection (GC-FID).
Following a request from EFSA about the source of aluminium, the applicant responded that the NF
is stored in aluminium boxes.
The applicant provided also the results from one batch on the total fatty acid profile of the NF (Table 2).
The applicant provided also information on heavy metals from two independent batches (Table 3),
showing low concentrations. In addition, five batches were also analysed for 3-monochloropropanediol
(3-MCPD) and glycidyl fatty acid esters, indicating much lower concentrations than those maximally
permitted in fats and oils according to Commission Regulation (EC) No 1881/2006 (Table 4).
Table 1: Batch to batch analysis of the NF
Parameter Method of Analysis
Batch Number
No 1 No 2 No 3 No 4 No 5
Colour
(AHPA colour)
AOCS Ea9-65 < 600 < 600 < 600 < 600 < 600
Acid value
(mg KOH/g)
AOCS Cd3d-63 0.8 0.7 0.7 0.4 0.8
Iodine value
(g I2/100 g)
AOCS Cd1-25 30.3 30.5 32.2 30.1 30.1
Saponification value
(mg KOH/g)
AOCS Cd3-25 134.4 138.2 138.6 141.3 136.6
Hydroxyl value
(mg KOH/g)
AOCS Cd13-60 6.3 7.1 6.0 4.1 7.4
Ester content (%) GC-FID 75.14 74.38 74.23 72.19 73.49
Cetyl oleate (%) GC-FID 23.95 23.80 23.77 23.10 23.48
Cetyl myristate (%) GC-FID 49.37 48.82 48.69 47.39 48.25
Triglycerides GC-FID 22.83 23.81 24.82 24.85 22.84
Aluminium (mg/kg) ICP-MS 1.57 1.26 1.03 1.49 1.70
APHA: American Public Health Association; AOCS: American Oil Chemists’ Society; GC-FID: gas chromatography with flame
ionisation detection; ICP/MS: inductively-coupled plasma mass spectroscopy; KOH: potassium hydroxide.
Table 2: The total fatty acid composition of the NF
Fatty acid Results
Oleic acid (%) 45.98
Myristic acid (%) 40.96
Linoleic acid (%) 7.97
Palmitic acid (%) 3.24
Stearic acid (%) 0.80
Palmitoleic acid (%) 0.44
Eicosenoic acid (%) 0.30
Lauric acid (%) 0.21
Eicosanoic acid (%) 0.11




No 6 No 7
Arsenic (mg/kg) < 0.005 NT ICP-MS
Cadmium (mg/kg) < 0.005 0.008
Mercury (mg/kg) < 0.005 < 0.005
Lead (mg/kg) 0.008 < 0.005
Nickel (mg/kg) 0.020 NT
ICP-MS: inductively coupled plasma mass spectrometry; NT: not tested.
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The applicant also analysed, although for only one batch, dioxins (0.13 pg/g) and polychlorinated
biphenyls, polycyclic aromatic hydrocarbons (1.3 lg/kg) and erucic acid (< 0.5 g/kg), showing
concentrations which are not of concern.
Microbiological contamination (Table 5) was provided from five batches.
Information was also provided on the accreditation of the laboratories that conducted the analyses
presented in the application.
The Panel considers that the information provided on the composition of the NF is sufficient and
does not raise safety concerns.
3.4.1. Stability
The applicant performed stability tests with five independently produced batches (1090l19/01–
1090l19/05) of the NF. The tests were carried out at 25  2°C for 12 months and under accelerated
conditions (40  2°C) for 9 months. The batches were analysed for the saponification and hydroxyl
values and all microbiological and physico-chemical specification parameters indicated in Table 1
except for triglycerides. At the end of 12 and 9 months, respectively, all tested parameters were within
the specification limits. Small changes of the saponification and hydroxyl value were noted, but are not
of concern. The provided stability data indicate that the NF is sufficiently stable for at least 12 months
under 25  2°C.
The Panel considers that the data provided sufficient information with respect to the stability of the
NF for a duration of 12 months.
3.5. Specifications
The specifications of the NF as proposed by the applicant are indicated in Table 6. The specification
parameters are assessed using internationally recognised methods or are otherwise determined using
internally developed and validated methods.
Table 4: Results for 3-MCPD and glycidyl fatty acid esters of five independent batches of the NF
Parameter
Batch number
No 8 No 2 No 3 No 4 No 5
3-MCPD (lg/kg) < 10 n.d. n.d. n.d. n.d.
Sum of 3-MCPD and 3-MCPD fatty acid
esters, expressed as 3-MCPD (lg/kg)
n.d. 210 230 260 240
Glycidyl fatty acid esters expressed as
glycidol (lg/kg)
340 300 400 320 290
n.d.: not detected; 3-MPCD: 3-monochloropropanediol.






No 1 No 2 No 3 No 4 No 5
Total aerobic microbial
count (CFU/g)
ISO 4833 < 1,000 < 1,000 < 100 < 1,000 1,000 1,000
Escherichia coli
(negative/g)




































ISO 21527-1/2 < 100 < 100 < 10 < 100 < 100 < 100
Enterobacter (CFU/g) ISO 6579 < 100 < 100 < 100 < 100 < 100 < 100
CFU: colony forming units; ISO: International Organization for Standardization.
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Although the applicant has proposed to add aluminium as a parameter to the specification, when
considering the source of aluminium, the low levels detected in the five batches (1.03–1.57 mg/kg NF)
and the proposed use levels, the Panel considers that no specification maximum is needed for this
parameter.
The Panel considers that the information provided on the specifications of the NF is sufficient and
does not raise safety concerns.
3.6. History of use of the NF and/or of its source
3.6.1. History of use of the source
The applicant refers to the history of fatty acids in the European diet. Myristic acid is found in
coconut oil, nutmeg butter, palm seed oil and milk fat, with small amounts detected in most animal
and vegetable oils (CIR, 1987). The applicant also notes esterified oleic acids found in many vegetable
oils and animal fats.
3.6.2. History of use of the NF
According to the applicant, the NF has no history of use outside of the EU, but a similar ingredient
‘cetyl myristoleate complex (CMC)’ has been authorised by the Korean Food and Drug Administration in
2009.
In its opinion from 2010 on another NF application for cetylated fatty acids, the Panel noted that
according to the applicant of that application, the concerned NF was produced and sold in quantities
over 10.000 kg CMC in the US between 1996 and 2008 with no adverse effects reported (EFSA NDA
Panel, 2010).
In the US, synthetic fatty alcohols, including cetyl alcohol is a food additive permitted for direct
addition to food for human consumption under certain conditions regarding production process, purity
(at least 98%) and use (FDA, 2020).
In 1999, JECFA estimated the daily per capita intake of cetyl alcohol as a flavouring agent to be
3.6 lg/day (JECFA, 1999).
3.7. Proposed uses and use levels and anticipated intake
3.7.1. Target population
Following a request from EFSA to provide clarification regarding intended target population, the
applicant clarified and confirmed that the target population is the general adult population only.
3.7.2. Proposed uses and use levels
The applicant proposes the use of the NF for food supplements at a use level of 2.1 g/day.
Table 6: Specifications of the NF
Parameter Specification
Physical status at 25°C Solid
Colour (APHA colour) ≤ 600
Acid value (mg KOH/g) ≤ 5
Iodine value (g I2/100 g) 30–50
Saponification value (mg KOH/g) 130–150
Hydroxyl value (mg KOH/g) ≤ 20
Ester content (%) 70–80
Cetyl oleate (%) 22–30
Cetyl myristate (%) 41–56
Microbiological criteria
Total aerobic microbial count (CFU/g) ≤ 1,000
Yeasts and moulds (CFU/g) ≤100
APHA: American Public Health Association; CFU: colony forming units; KOH: potassium hydroxide.
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3.8. Absorption, distribution, metabolism and excretion (ADME)
No ADME studies were provided for the NF or with other cetylated fatty acids. The applicant
referred to the ADME on triglycerides, fatty acids and the EFSA Opinions on another, similar NF
application (‘CMC’) (EFSA NDA Panel, 2010, 2013).
In 2008, the EFSA Panel on Food Additives, Flavourings, Processing Aids and Materials in contact
with Food (AFC) concluded on 40 different linear- and branched-chain aliphatic saturated primary
esters with an alkyl chain length of up to C7, that these esters would undergo hydrolysis to yield their
corresponding linear- or branched-chain aliphatic alcohols and linear carboxyl acids and that any
remaining non-hydrolysed esters are expected to be absorbed rapidly from the gastrointestinal tract as
well, after which they are also expected to be hydrolysed (EFSA AFC Panel, 2008).
In their Opinion from 2008, the EFSA AFC Panel also summarised available data on the fate of cetyl
alcohol (citation): ‘Data for the C16 aliphatic alcohol, hexadecan-1-ol (cetyl alcohol), indicate that of
the 34% total absorbed (recovered in thoracic duct lymph, carcass, liver, expired CO2, and urine) of a
dose in corn oil administered by oral gavage to male Sprague-Dawley rats, 75% was found in the
thoracic duct lymph after 24 h and that 85% of this material had been converted to fatty acid,
presumed to be palmitic acid (Baxter et al., 1967). Another study corroborates this result in that cetyl
alcohol was well absorbed (63–96%, based on the difference between amount administrated and
amount recovered from the intestinal tract and faeces) when fed to rats. From 31% to 64% of the
absorbed material was recovered from the thoracic lymph lipids. About 15% of this amount was
present as unchanged cetyl alcohol. The remainder had been oxidised to palmitic acid and
subsequently incorporated into triglycerides and phospholipids. The main part of this oxidation process
took place during the passage of the lipids through the intestinal mucosa cells (Blomstrand & Rumpf,
1954).’ According to the JECFA (1999), such linear alcohols (including cetyl alcohol) are rapidly
absorbed from the gastrointestinal tract. Information on distribution and excretion of these compounds
has not been submitted, but these flavouring substances can be expected to be extensively
metabolised to substances that are easily excreted by animals and humans. According to JECFA
(1999), cetyl alcohol is oxidised to hexadecanal which is rapidly oxidised to hexadecanoic acid which is
metabolised via the fatty acid and tricarboxylic acid pathways.
In the opinion on the NF application ‘CMC’ from 2010, the NDA Panel noted that there is some
information that long-chain fatty acid esters are hydrolysed but at a slow rate.
3.9. Nutritional information
Taking into account the composition of the NF and the proposed maximum intake of NF, i.e. 2.1 g
per day, the Panel considers that the NF is not nutritionally disadvantageous.
3.10. Toxicological information
The applicant provided four toxicological studies performed with the NF, an in vitro bacterial reverse
mutation test (Thompson, 2017) in compliance with the OECD Guidance No. 471 (OECD, 1997), an
in vitro mammalian cell micronucleus test (Morris, 2017) in accordance with OECD Guidance No 487
(OECD, 2016), a non-GLP compliant 14 day subacute study (Piras, 2019) and a subchronic toxicity
study following OECD Guidance No. 408 (OECD, 2018) (Piras, 2020). The respective study reports are
unpublished and claimed proprietary by the applicant. The two in vitro genotoxicity studies and the
subchronic toxicity study have been published in an article by Brilli and Tarantino (2020).
3.10.1. Genotoxicity
In the in vitro bacterial reverse mutation assay, Salmonella typhimurium strains TA1535, TA1537,
TA98 and TA100 and Escherichia coli strain WP2uvrA were treated with the NF (Thompson, 2017). In this
study, the test item was non-mutagenic at concentrations up to 5,000 lg/plate, in the absence or
presence of metabolic activation. In an in vitro mammalian cell micronucleus test with human
lymphocytes compliant with OECD Guidance No 487 and GLP with and without metabolic activation
(Morris, 2017), the test item was not clastogenic or aneugenic.
Regarding cetyl alcohol, in 2010, the EFSA NDA Panel noted literature which showed negative
results in genotoxicity studies (EFSA NDA Panel, 2010). In their assessment of long-chain alcohols,
which covered also cetyl alcohol, OECD (2006) concluded that the category of long chain alcohols does
not have genotoxic potential.
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Taking into account the information provided on the raw material used, the production process, the
composition of the NF and the test results of the two provided in vitro genotoxicity tests, the
Panel considers that there are no concerns regarding genotoxicity.
3.10.2. Subacute toxicity
In a subacute toxicity study in rats, not in compliance with GLP and the respective OECD Guidance
document, the NF was given by gavage at doses of 0, 1,600, 1,900, 2,200, 2,600 and 4,500 mg/kg
per day for 14 days (Piras, 2019). A lower glucose plasma level in the high-dose group animals was
the only potentially relevant finding.
3.10.3. Subchronic toxicity
The applicant provided a 90-day repeated dose toxicity study by Piras (2020) with Sprague-Dawley rats
in compliance with the OECD principles of GLP (OECD, 1998) and according to OECD Guidance No 408
(OECD, 2018). Groups of 10 male and 10 female Sprague-Dawley rats received 0 (vehicle control = corn
oil), 1,500, 3,000 or 4,500 mg/kg bw per day of the NF (batch number 1090L18/01) by oral gavage at a
dose volume of 10 mL/kg bw per day, each as two separate daily doses (60–150 min apart) for 90 days. An
additional ‘reference control’ group (comprising the same number of animals) received 4,500 mg/kg bw
per day of a mixture of 24% myristic acid, 13% oleic acid derived from olive oil with a purity of 78%, and
63% refined olive oil. All formulations were heated to 51°C before dosing (dosing temperature of
~ 47°C), due to nature of the test article and reference control, which both otherwise solidified at lower
temperatures. Additionally, five males and five females, in each of the vehicle control, high-dose and
reference control groups were employed as recovery groups.
There were no deaths during the 90 days, no test item-related clinical signs observed in the weekly
assessment and no ophthalmological changes observed at the end of the treatment. In the functional
observation battery (FOB) assessments (including assessment of sensory reactivity to different stimuli,
grip strength and motor activity) during the 11th week of the treatment, female rats of the mid- and
high-dose group showed a statistically significant decrease in crossing motor activity. Since no such
differences were observed for male animals, and no differences in the other endpoints of the FOB or
other clinical sign in either sex, the Panel considered that the difference in the motor activity observed
in the female rats of the mid and high dose was toxicologically not relevant.
There were no differences in body weight or food consumption between test item groups and the
vehicle controls in both sexes. The fact that 4,500 mg of the vehicle control (corn oil) per kg bw per
day represents a significant proportion of the daily energy intake of this group and that no difference
in food consumption and body weight was observed among all groups, suggest that the cetylated fatty
acids have been utilised as a source of energy.
Regarding clinical haematology and clinical chemistry assessments, the following parameters
showed statistically significant differences between vehicle controls and test item groups: reduced (by
about 3%) mean corpuscular haemoglobin concentration of high-dose males and the reference control
males, and in females of the high-dose group (reduction by about 2%). Given the small differences
and considering that there was no other affected endpoint related to red blood cells and haemoglobin,
the Panel considers that these differences are toxicologically not relevant.
Compared to the vehicle control, there were further statistically significant differences such as: an
increase of the prothrombin time in low-dose males and females, mid-dose males and reference
control males and females, increased platelets in mid-dose females, increased glucose in low-dose
females, reduced total protein and albumin in low- and mid-dose males and an increase of urea in low-
and mid-dose males. In the absence of a dose–response relationship, and given that these findings
were only seen in low- and mid-dose animals, the Panel considers these findings as incidental.
Statistically significant differences were observed between the vehicle control and the high-dose
female rats: a lower urea (–26%), an increase in sodium (+6.1%) and a 43% higher plasma potassium
concentration. The Panel notes the high variation for urea in plasma. It was statistically significant
higher in the low- and mid-dose male rats relative to the vehicle control, but not in the high-dose male
rats. Among the recovery groups, the potassium values were statistically significantly higher in both
the female and male of the high dose and the reference control groups compared to the vehicle
control group. While a 6.1% increase of sodium in the female high-dose group compared to the
vehicle control was the only statistically significant difference among the measured sodium plasma
concentrations in the three male and female treatment groups, statistically significant higher sodium
was also reported for the recovery reference control groups in both sexes. Noting also that there were
Safety of Cetylated Fatty Acids as a Novel Food
www.efsa.europa.eu/efsajournal 10 EFSA Journal 2021;19(7):6670
no statistically significant differences in the absolute and relative kidney weights and in the urinalysis,
and no histopathological findings in the kidney, the Panel considers that the reported statistical
differences in the high-dose female rats for urea, sodium and potassium are not of toxicological
relevance.
There were no statistically significant differences in thyroid hormones between controls and test
item groups. There were no test item-related differences in absolute and relative organ weights,
except for statistically significant increases for absolute and relative pancreas weights for females in all
dose groups and a reduced urinary bladder weight for low-dose females. However, these differences
were not associated with a dose response and no test item-related macroscopic and histopathological
findings were observed in the pancreas.
Histopathological findings of potential relevance were observed in the salivary glands, stomach,
aorta and lungs. In all groups, including the vehicle and reference control group, animals were found
at the end of 13 weeks with acinar cell degeneration and/or atrophy of the salivary glands. Such
effects in the salivary glands were also reported after the recovery period for animals of the vehicle
and reference control, but not for the high-dose animals. Also in all groups, including recovery groups,
animals were found with superficial disruption in the glandular part of the gastric mucosa. The
incidence of this finding in the stomach was lowest in the vehicle control (11/20) and highest in the
high dose (19/20) and reference control group (19/20). The number of affected animals was similar
among the recovery groups (9/10 for the vehicle control; and 7/10 for both the high dose and the
reference control). The Panel considers that these treatment-related effects were due to the gavage
administration of the heated test materials.
The study report also shows that emphysematous pictures were seen in the lungs of animals in all
groups with the lowest incidence in the vehicle control (1/20) and the highest incidence in the
reference control group (11/20). There was no dose-response among the three dose groups: each 10
affected animals in the low and mid-dose, and 9 in the high dose. The incidence among the recovery
groups was similar (each 7/10 in the vehicle and high-dose group and 8/10 in the reference control
group). Lung emphysema has been reported as a common effect in the review by Iwarsson and
Rehbinder (1993) when CO2 is used as euthanasia methods in rats, mice and guinea pigs. The animals
in the 90-day study were killed by CO2. In the absence of a dose-response and noting the high
incidence of this effect for the vehicle control recovery group, the Panel considers that the effects were
not related to toxicity of any of the tested materials.
Regarding aorta, no animal in the vehicle control group, but 2/20, 1/20, 4/20 and 3/20 animals in
the low, mid, high dose and the reference control group, respectively, had areas of early degeneration.
Considering that 1) there was no dose-response, 2) that also three animals of the reference control
and 3) that 1/10 animals of the vehicle and 1/10 animals of the reference control, but no animal of the
high-dose group had such a finding after the recovery period, the Panel considers that these findings
are not of toxicological relevance for the NF.
Overall, the Panel notes that histopathological findings in the three dose groups were seen in either
one or both of the control groups at the end of 13 weeks and/or at the end of the recovery period.
The Panel also notes that the findings in the high-dose groups and the reference control group were
essentially the same. The Panel considers that the histopathological findings in the two control groups
were not related to corn oil toxicity, the fatty acids and/or olive oil, but rather due to the treatment
with the heated test materials administered by gavage and possibly also to the euthanasia with CO2
(lungs) as performed in this study. The Panel is of the view that the same applies to the
histopathological findings of the three test groups receiving the NF. This consideration is supported by
the absence of any other statistically significant finding considered to be related to the administration
of the test materials. Consequently, the Panel considers that the highest dose tested, i.e. 4,500 mg/kg
bw per day of the NF, is the NOAEL of this subchronic study.
3.10.4. Human data
The Panel notes that there are no human studies conducted with the NF available.
3.11. Allergenicity
Cetyl alcohol is a known contact allergen (Aakhus and Warshaw, 2011; Gaul, 1969; Komamura
et al., 1997; van Ketel, 1984). The Panel considers that is unlikely to cause allergenic reactions under
the intended uses.
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4. Discussion
The NF concerns a mixture composed of cetylated fatty acids (about 83%) made from cetyl
alcohol, and myristic acid and oleic acid. The NF contains also smaller amounts of other cetylated fatty
acids (such as linoleic and palmitic acid) from esterification of fatty acids contained in refined olive oil.
While there is long and substantial history of human consumption of olive oil, oleic acid and also
myristic acid, no such data exist for cetyl alcohol or cetylated myristic and cetylated oleic acid. In order
to address potential subchronic toxicity, the applicant provided a 90-day study with rats. In the
absence of toxicity related to the NF observed in this study, the Panel considers that the NOAEL of this
subchronic study was the highest dose tested, i.e. 4,500 mg/kg bw per day. By applying the default
uncertainty factor of 200 as suggested by the EFSA Scientific Committee (2012), and considering a
default body weight of 70 kg for the adult target population, this would result in an intake of 1.6 g per
day, which is lower than the maximum intake proposed by the applicant (i.e. 2.1 g per day).
5. Conclusions
The Panel concludes that the NF, cetylated fatty acids, is safe at an intake of 1.6 g per day for the
intended target population, i.e. adults.
The Panel could not have reached the conclusion on the safety of the NF under the proposed
conditions of use without the data claimed as proprietary by the applicant (Morris, 2017; Thompson,
2017; Piras, 2020) as well as a summary table of statistically significant observations in toxicity studies
(appendix B3), annex III (certificates of analysis, batch testing and methods of analysis) and annex IV
(stability data).
6. Steps taken by EFSA
1) On 20/07/2020 EFSA received a letter from the European Commission with the request for a
scientific opinion on the safety of cetylated fatty acids as a novel food. Ref. Ares (2020)
3814185.
2) On 20/07/2020, a valid application on cetylated fatty acids as a novel food (NF 020/1828),
which was submitted by Pharmanutra S.p.A., was made available to EFSA by the European
Commission through the Commission e-submission portal (NF 2020/1828) and the scientific
evaluation procedure was initiated.
3) On 06/10/2020 and 12/02/2021, EFSA requested the applicant to provide additional
information to accompany the application and the scientific evaluation was suspended.
4) On 16/10/2020 and 23/04/2021, additional information was provided by the applicant
through the Commission e-submission portal and the scientific evaluation was restarted.
5) During its meeting on 26/05/2021, the NDA Panel, having evaluated the data, adopted a
scientific opinion on cetylated fatty acids as a NF pursuant to Regulation (EU) 2015/2283.
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Abbreviations
ADME absorption, distribution, metabolism and excretion
AFC Panel on Food Additives, Flavourings, Processing Aids and Materials in contact with Food
AOCS American Oil Chemists’ Society
APHA American Public Health Association
Bw body weight
CAS Chemical Abstract Services
CFA cetylated fatty acids
CFU colony forming units
CIR Cosmetic Ingredients Review
CMC Cetyl Myristoleate Complex
CoA Certificate of Analysis
CONTAM Panel on Contaminants in the Food Chain
FA fatty acid
FDA Food and Drug Administration
FOB functional observation battery
GC-FID gas chromatography with flame ionisation detection
GLP Good Laboratory Practice
GMP Good Manufacturing Practice
HACCP Hazard Analysis Critical Control Points
ICP-MS Inductively-coupled plasma mass spectrometry
ISO International Organization for Standardization
JECFA Joint FAO/WHO Expert Committee on Food Additives
KOH potassium hydroxide
MCPD monochloropropanediol
NDA Panel on Nutrition, Novel Foods and Food Allergens
NOAEL no observed adverse effect level
NF Novel Food
OECD Organisation for Economic Co-operation and Development
US United States
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